74 search results for: symposium
Key Treatment Considerations for Management of Atopic Dermatitis in Children
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the key considerations for management of AD that is uncontrolled with topical therapies in children and the criteria to determine whether a patient is indicated for systemic therapy
ADVENT at UEG WEEK 2025 | Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care
Join Thomas Greuter, MD, Edoardo Vincenzo Savarino, MD, PhD, and Carla Giordano, MD, PhD, for an educational symposium as they use a case-based approach to explore the impact of chronic type 2 inflammation in EoE and outline strategies for optimizing transition of care and monitoring disease progression.
ADVENT at WCPD 2025
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
Identification and Management of AD Uncontrolled With Topical Therapies in Children
In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE).
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.
Shifting Gears: Can Disease Course Be Changed in Patients With Pediatric Atopic dermatitis?
In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Amy Paller, MD and Dr. Peter Lio, MD discusses the role of atopic dermatitis as a risk factor for developing food allergies. Moreover, explores the potential opportunities for early intervention to alter disease trajectories and the possibilities for disease modification in atopic dermatitis.
Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis
Join Christine Bangert and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a Symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE). This event is neither sponsored by nor endorsed by ACG.
Type 2 Inflammation
In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Lio, MD and Dr. Amy Paller, MD discusses the multifaceted nature of atopic diseases, including environmental triggers, key Type 2 inflammatory mechanisms, and associated health risks, to understand the importance of early intervention in managing and potentially modifying disease progression.
ADVENT at ESPGHAN 2025 | Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients
In support of World Eosinophilic Esophagitis Day, this ADVENT symposium features pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
